In short
- Four people who had taken part in psilocybin or DMT trials met in focus groups and a workshop to reflect on their experience.
- They described how communication, the relationship with staff and not knowing whether they had received the real treatment shaped everything.
- Dosing felt like the start of a process, not the end, and when the study finished some felt loss and grief. All said more support afterwards would have helped.
What the researchers did
Researchers worked with members of the Psychedelic Participant Advocacy Network (PsyPAN), people with lived experience of psychedelic trials for depression or an eating disorder. Over three online focus groups they talked through each stage, from recruitment to the end of the study, and then developed recommendations together.
What they found
Five themes stood out. Participants came looking for help but met procedures built for research. “Set and setting” extended to the whole trial: how staff spoke to them, uncertainty about their group and time-limited support. Facilitators played a key role in balancing protocol and human needs. The dose was the beginning of meaning-making and change. And the end of the study was hard for some, with too little access to psychedelic-informed care.
Why it matters
It is easy to focus on the session and forget the person who walks out of it. These accounts are a reminder that people need clear expectations before, warmth and attention during, and someone to turn to afterwards. That is why our guests do not simply go home after a retreat: integration sessions and a community that stays in touch are part of what we offer, and our free monthly Numinous Dialogues are open to anyone who wants to keep talking.
Keep in mind
Only four people took part, all from one advocacy network, so their views may not represent all participants. The study is qualitative: it describes experiences rather than measuring outcomes.
Making sense of an experience
Our psychologists and psychotherapists offer one-to-one integration sessions, online or in Edinburgh.
Integration therapyThis summary is for information only and is not medical advice. Psychedelics are controlled substances in many countries, including the UK.
You may also like
A Wider Stage: How Psychedelics Reorganise the Workspace of Consciousness
Brain scans suggest LSD, psilocybin and mescaline add more information-gathering hubs to the brain’s global workspace, the stage on which consciousness plays out.
Dr Christoph Zwolan · 13 November 2026
ResearchWhen the Self Falls Quiet: Ego Dissolution and the Language of the Self
A brain-imaging study found that during strong ego dissolution on psilocybin, people’s language and meaning networks became more alike.
Dr Christoph Zwolan · 12 November 2026
ResearchBelonging, Gratitude and Purpose: Beyond Symptom Relief
In an MDMA-assisted therapy trial for social anxiety, moments of connection and self-transcendent emotion predicted greater belonging, gratitude and purpose.
Danielle Tanner · 10 November 2026
